STIMIT is Enrolling Patients in Clinical Trial of Noninvasive Diaphragm Neurostimulation Device

BIEL, Switzerland–(BUSINESS WIRE)–STIMIT AG announced it is enrolling patients in its FDA Investigational Device Exemption (IDE) clinical trial, “STIMIT ACTIVATOR 1 PIVOTAL STUDY,” with world renowned clinical centers, thus pioneering a transformation in ventilation and critical care. STIMIT’s initial therapy in its platform uses noninvasive diaphragm neurostimulation and is designed to preserve diaphragm thickness in patients who are on invasive mechanical ventilation (MV).
Zum Beitrag auf Businesswire